Infective endocarditis is microbial infection of the endovascular structures of the heart.
It often presents in an occult fashion and early diagnosis depends on a high index of clinical suspicion especially in patients with congenital heart disease, prosthetic valves or previous infective endocarditis.
The established diagnosis of infective endocarditis is demonstrated by a positive blood culture and involvement of the endocardium detected during sepsis or systemic infection. It may also be established if there is involvement of the endocardium detected during sepsis or systemic infection but blood culture is negative.
Long-term results of the POET* trial have suggested that patients with left-sided infective endocarditis (IE) could safely switch from conventional intravenous (IV) antibiotics to oral antibiotics, with oral antibiotics associated with a reduced mortality risk.
Outpatient parenteral antibiotic treatment (OPAT) may be a suitable option for individuals with infective endocarditis compared with hospital-based antibiotic treatment (HBAT), a recent study from Spain showed.
In patients with left-sided infective endocarditis in stable condition, switching to oral antibiotics is as effective and safe as continued treatment with intravenous (IV) antibiotics, according to results of the POET trial reported at the European Society of Cardiology (ESC) Congress 2018.
New drug applications approved by US FDA as of 1 - 15 September 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Infective endocarditis in very elderly patients frequently occurs due to Enterococci and is associated with higher mortality compared with that in younger patients, a study has shown. Moreover, surgery—which carries an excellent prognosis—appears to be underutilised in the octogenarian population, yielding high mortality in those who have not undergone an operation.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Infectious Diseases - Malaysia digital copy today!
The guideline-recommended, single-tablet, fixed-dose regimen comprising bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) was noninferior to the dolutegravir and F/TAF (D/F/TAF) regimen in persons living with HIV (PLHIV), according to data presented at IAS 2019.